MedTrace Logo

Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

NCT04071613 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2021-12-08

No results posted yet for this study

Summary

Ischemic stroke is a major health burden globally and in Australia. Treatment for ischemic stroke is time critical and is significantly more effective if administered within the first 90 minutes of symptom onset. This clinical trial will identify if early administration of oral thrombolytic agent, tenecteplase prior to hospital can improve outcomes from stroke, and reduce costs compared to standard care of IV alteplase in hospital

Conditions

  • Stroke, Acute, Stroke Ischemic

Interventions

DRUG

Tenecteplase

Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset

DRUG

Intravenous tissue plasminogen activator (tPA)

Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset

Sponsors & Collaborators

  • Melbourne Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-20
Primary Completion
2021-11-16
Completion
2021-11-16

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04071613 on ClinicalTrials.gov